Vetter, a globally recognized contract development and manufacturing organization (CDMO), proudly announces the successful market introduction of eight customer drug products by the end of 2023. This achievement underscores Vetter's pivotal role in advancing drug development and commercialization, especially in the realms of oncology, autoimmune, and cardiovascular diseases.

The commercialized drugs, benefiting from Vetter's comprehensive Development Service portfolio, vary significantly in their application, ranging from emergency use to long-term therapeutic treatments. These products also differ in their administration methods, catering to both self-administered at-home care and professional healthcare settings, thus enhancing patient-centric treatment options.

Dr. Claus Feussner, Senior Vice President of Vetter Development Service, highlighted the intricate journey from drug conception to market launch, emphasizing the seamless integration of Vetter's development services. "Our holistic approach to drug development and commercialization has been instrumental in bringing these therapies to market. It's a testament to our commitment to supporting our clients through every stage of the product lifecycle," stated Dr. Feussner.

Over the past five years, Vetter's unique capabilities have contributed to over 50 market launches, showcasing its expertise and innovation in the pharmaceutical industry. The company's recent expansions in clinical capabilities, including production, analytical services, and skilled personnel, further strengthen its position as a leader in the field.

Vetter's Development Service, alongside its Commercial Manufacturing and Secondary Packaging and Assembly divisions, forms a robust foundation for the CDMO's operations. Currently, Vetter is involved in over 200 projects at various stages of clinical development, demonstrating its comprehensive support for the pharmaceutical industry's evolving needs.

With state-of-the-art clinical manufacturing facilities in Skokie, USA, and Rankweil, Austria, Vetter is equipped to handle early-stage clinical batch production. Additionally, its Ravensburg site in Germany is dedicated to late-stage development, encompassing process design and quality production, ensuring a smooth transition from development to commercial launch.

This milestone reflects Vetter's unwavering dedication to innovation, quality, and patient care, reinforcing its status as a trusted partner in the pharmaceutical industry.